Traws Pharma, Inc. — Director's Dealing 2021

Feb 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2021-02-17

Reporting Person: Fruchtman Steven M (Director, President, Chief Executive Off)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-17	Stock Appreciation Right	$1.51	A	706000	Acquired	2031-02-17	Common Stock (706000)	Direct

Footnotes

F1: These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.

F2: These stock appreciation rights represent the right to receive a cash payment equal to the excess, if any, of (i) the fair market value of each underlying share of the Company's common stock, determined on the date of exercise minus (ii) the exercise price; provided, that in no event may the cash payment for each stock appreciation right exceed $1.03, which is the maximum price per share of $2.54, minus the base amount of $1.51, subject to adjustment in accordance with the terms of the award agreement.